Core Viewpoint - Asia-Pacific Pharmaceutical (002370) reported a significant increase in net profit due to the sale of a subsidiary, despite a decline in revenue [1] Financial Performance - The company achieved an operating revenue of 228 million yuan in the first three quarters, a year-on-year decrease of 25.59% [1] - The net profit attributable to shareholders reached 97.195 million yuan, marking a year-on-year increase of 2909.49% [1] - The non-recurring net profit was -56.5853 million yuan, reflecting a year-on-year decline of 150.47% [1] Key Events - The substantial increase in net profit was primarily attributed to the sale of 100% equity in its wholly-owned subsidiary, Shaoxing Xingya Pharmaceutical Co., Ltd., which contributed approximately 149 million yuan to the total profit [1]

Group 1 - Company reported Q3 performance with revenue of approximately 228 million yuan, a year-on-year decrease of 25.59% [1] - Net profit attributable to shareholders was approximately 97.2 million yuan, a year-on-year increase of 2909.49% [1] - Basic earnings per share increased to 0.1313 yuan, a year-on-year increase of 2444.64% [1] Group 2 - As of the report, the market capitalization of the company is 5.3 billion yuan [2]

亚太药业公告，第三季度营收为7623.1万元，下降10.21%；净利润亏损798.15万元。前三季度营收为 2.28亿元，下降25.59%；净利润为9719.5万元，增长2,909.49%。 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥76,231,043.79, a decrease of 10.21% compared to the same period last year[4] - The net profit attributable to shareholders was -¥7,981,457.60, an increase of 10.67% year-on-year, while the net profit after deducting non-recurring gains and losses was -¥7,723,092.55, a decrease of 47.69%[4] - The total operating revenue for the current period is CNY 228,305,775.20, a decrease of 25.6% compared to CNY 306,835,789.08 in the previous period[20] - The operating profit for the current period is CNY 97,259,904.67, compared to a loss of CNY 3,202,585.73 in the previous period, indicating a significant turnaround[21] - The net profit for the current period is CNY 97,195,012.22, a recovery from a net loss of CNY 3,459,530.47 in the previous period[21] - The total comprehensive income attributable to the parent company is ¥97,195,012.22, showing a significant recovery from a loss of ¥2,861,149.28 in the prior period[22] - Basic and diluted earnings per share are both ¥0.1313, an improvement from a loss of ¥0.0056 per share in the previous period[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,213,947,013.65, down 13.40% from the end of the previous year[4] - The company's total assets as of September 30, 2025, are CNY 1,213,947,013.65, down from CNY 1,401,768,368.44 at the beginning of the period, representing a decrease of 13.4%[18] - The total liabilities decreased to CNY 92,772,945.76 from CNY 429,587,364.82, a reduction of 78.4%[18] - The company's cash and cash equivalents decreased to CNY 587,809,931.97 from CNY 743,850,694.68, a decline of 21.0%[17] - The inventory level decreased to CNY 52,774,054.96 from CNY 70,128,529.14, reflecting a reduction of 24.8%[17] Cash Flow - The cash flow from operating activities was ¥23,548,958.18, a decrease of 34.35% compared to the same period last year, mainly due to reduced sales receipts[10] - Cash flow from operating activities generated a net cash inflow of ¥23,548,958.18, down from ¥35,870,275.86 in the previous period[24] - Cash inflow from investment activities totaled ¥209,132,163.04, a substantial increase from ¥2,026,063.67 in the prior period[24] - The net cash flow from investment activities is ¥144,780,598.41, recovering from a net outflow of ¥5,107,308.62 in the previous period[24] - Cash and cash equivalents at the end of the period decreased to ¥573,431,601.51 from ¥689,103,730.30 in the previous period[25] - The company repaid debts amounting to ¥277,225,300.00 during the financing activities, compared to ¥50,000,000.00 in the previous period[24] - The total cash outflow from financing activities was ¥314,596,678.34, significantly higher than ¥61,901,761.80 in the prior period[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 91,465[12] - The largest shareholder, Ningbo Fubon Holdings Group, holds 11.99% of shares, totaling 89,420,000 shares[12] - A share transfer agreement was signed on October 13, 2025, involving the transfer of 14.61% of shares (108,945,566 shares) at a price of 8.26 CNY per share, totaling 900 million CNY[13] - After the share transfer, the controlling shareholder will change from Fubon Group to Xinghao Holdings[13] - The company plans to issue A-shares to specific investors, including Zhejiang Xinghao Holdings, pending approval from the shareholders' meeting and regulatory bodies[14] - The share transfer will result in a change of actual control from a management team to Qiu Zhongxun[13] - The top ten shareholders hold a significant portion of shares, with the top two alone accounting for 14.61%[12] - The company has not disclosed any changes in the status of preferred shareholders or their holdings[12] Regulatory and Risk Factors - The share transfer and issuance are subject to regulatory approval, which introduces uncertainty[14] - Investors are advised to analyze the situation carefully due to potential risks associated with the changes in control and share issuance[13] Other Income and Expenses - The company reported a significant increase in investment income of ¥150,238,252.18, up 847.65% year-on-year, primarily due to the sale of its subsidiary[9] - The company’s financial expenses increased by 69.97% to ¥27,893,904.81, mainly due to interest payments on convertible bonds[9] - The company reported a significant increase in other income of ¥5,509,405.28, up 118.12% year-on-year, primarily due to increased government subsidies[9] - The weighted average return on net assets was -0.71%, a decrease of 0.71% year-on-year[4] - The company’s basic and diluted earnings per share were both -¥0.0107, an increase of 25.17% compared to the same period last year[4] Organizational Changes - The company has completed the registration procedures for the change of its subsidiary structure, transitioning from a secondary to a primary subsidiary[15] - The company plans to optimize its organizational structure and improve operational efficiency through the proposed subsidiary changes[15]

Core Viewpoint - Asia-Pacific Pharmaceutical (002370) announced a significant change in its shareholding structure, with a transfer of 14.61% of its shares from its current controlling shareholder, Fubon Group, to Xinghao Holdings, which will result in a new actual controller [1] Group 1: Share Transfer Details - On October 13, Fubon Group and its action-in-concert party, Hangu Investment, signed a share transfer agreement with Xinghao Holdings and Xingchen Investment [1] - The share transfer involves 14.61% of the company's shares at a price of 8.26 yuan per share, totaling 900 million yuan [1] - Following the completion of this transfer, the controlling shareholder will change from Fubon Group to Xinghao Holdings, and the actual control will shift from the management team led by Song Hanping, Fu Cai, and Hu Zhenghui to Qiu Zhongxun [1] Group 2: Investment Structure Adjustment - The announcement also mentioned an adjustment in the investment structure of one of the transferees, Xingchen Investment, which has changed its original limited partner from Anji Jiuheng Venture Capital Co., Ltd. and Anji Shuzhi New Economy Equity Investment Partnership (Limited Partnership) to only Anji Jiuheng Venture Capital Co., Ltd. [1] - Both Anji Jiuheng Venture Capital and Anji Shuzhi New Economy are subsidiaries of the Anji County Finance Bureau [1]

Core Viewpoint - Asia-Pacific Pharmaceutical announced a significant share transfer agreement involving its controlling shareholder, Ningbo Fubang Holding Group, which will result in a change of control of the company [1] Group 1: Share Transfer Details - The controlling shareholder, Ningbo Fubang Holding Group, and its concerted party, Shanghai Hangu Investment Management, signed a share transfer agreement on October 13, 2025 [1] - A total of 14.61% of the company's shares, amounting to 108,945,566 shares, will be transferred at a price of 8.26 yuan per share, totaling 900 million yuan [1] - Starry Horizon Holdings will acquire 60,525,314 shares from Fubang Group, while Starry Morning Investment will acquire 28,894,686 shares and 19,525,566 shares from Fubang Group and Hangu Investment, respectively [1] Group 2: Change of Control - Following the completion of this share transfer, the controlling shareholder will change from Fubang Group to Starry Horizon Holdings [1] - The actual controllers of the company will shift from a management team consisting of Song Hanping, Fu Cai, and Hu Zhenghui to Qiu Zhongxun [1]

浙江亚太药业股份有限公司详式权益变动报告书 浙江亚太药业股份有限公司 详式权益变动报告书 （修订稿） 上市公司名称：浙江亚太药业股份有限公司 股票上市地点：深圳证券交易所 股票简称：亚太药业 股票代码：002370 信息披露义务人：浙江星浩控股合伙企业（有限合伙） 住所：浙江省湖州市安吉县灵峰街道清远路1397号10幢2楼231室 通讯地址：浙江省湖州市安吉县灵峰街道清远路1397号10幢2楼231室 股份变动性质：增加（协议受让、取得上市公司发行的新股） 一致行动人：浙江星宸股权投资合伙企业（有限合伙） 住所：浙江省湖州市安吉县灵峰街道清远路1397号10幢1楼135室 通讯地址：浙江省湖州市安吉县灵峰街道清远路1397号10幢1楼135室 股份变动性质：增加（协议受让） 签署日期：二〇二五年十月 浙江亚太药业股份有限公司详式权益变动报告书 信息披露义务人及其一致行动人声明 一、本报告书系根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第15号 ——权益变动报告书》《公开发行证券的公司信息披露内容与格式准则第16号— —上市公司收购报告 ...

证券代码：002370 证券简称：亚太药业 公告编号：2025-086 一、本次协议转让情况概述 浙江亚太药业股份有限公司 关于筹划公司控制权变更事项进展暨受让方股权结构调整 的公告 浙江亚太药业股份有限公司（以下简称"公司"）控股股东宁波 富邦控股集团有限公司（以下简称"富邦集团"）及一致行动人上海 汉贵投资管理有限公司（以下简称"汉贵投资"）于 2025 年 10 月 13 日与浙江星浩控股合伙企业（有限合伙）（以下简称"星浩控股"） 及浙江星宸股权投资合伙企业（有限合伙）（以下简称"星宸投资"） 签署了《股份转让协议》，富邦集团和汉贵投资拟通过协议转让方式 转让公司 14.61%股份，共计 108,945,566 股，转让价格为 8.26 元/ 股，合计总金额为 90,000.00 万元，其中星浩控股受让富邦集团持有 的公司 60,525,314 股股份，星宸投资受让富邦集团、汉贵投资分别 持有的公司 28,894,686 股股份、19,525,566 股股份。本次协议转让 完成后，公司的控股股东将由富邦集团变更为星浩控股，公司的实际 控制人将由宋汉平、傅才、胡铮辉组成的管理团队变更为邱中勋。本 次事项 ...

关于 国联民生证券承销保荐有限公司 浙江亚太药业股份有限公司 详式权益变动报告书 之 财务顾问核查意见 （修订稿） 二〇二五年十月 国联民生承销保荐财务顾问核查意见 声 明 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收 购管理办法》《公开发行证券的公司信息披露+内容与格式准则第15号——权益 变动报告书》《公开发行证券的公司信息披露内容与格式准则第16号——上市 公司收购报告书》等法律法规的规定，国联民生证券承销保荐有限公司按照证 券行业公认的业务标准、道德规范和勤勉尽责精神，对本次信息披露义务人披 露的《浙江亚太药业股份有限公司详式权益变动报告书》进行核查，并出具核查 意见。 为使相关各方恰当地理解和使用本核查意见，本财务顾问特别声明如下： 1、本财务顾问已按照规定履行了尽职调查义务，对信息披露义务人披露的 《详式权益变动报告书》进行了核查，确信披露文件内容与格式符合规定，并保 证所发表的专业意见与信息披露义务人披露内容不存在实质性差异； 2、本财务顾问所依据的有关资料由信息披露义务人提供。信息披露义务人 已做出声明，保证其所提供的所有文件、材料及口头证言真实、准确、完整、及 时，不存在 ...

Market Overview - The Shanghai Composite Index rose by 0.22% on October 23, with 21 out of 28 sectors experiencing gains. The top-performing sectors were coal and oil & petrochemicals, with increases of 1.75% and 1.53% respectively. Conversely, the telecommunications and real estate sectors saw declines of 1.51% and 0.99% respectively [1] Capital Flow Analysis - The main capital flow showed a net outflow of 33.733 billion yuan across the two markets. Six sectors experienced net inflows, with the coal sector leading at a net inflow of 1.465 billion yuan, followed by the media sector with a net inflow of 362 million yuan [1] - A total of 25 sectors faced net outflows, with the electronics sector experiencing the largest outflow of 5.435 billion yuan, followed by the machinery equipment sector with an outflow of 4.999 billion yuan. Other sectors with significant outflows included pharmaceuticals, telecommunications, and electrical equipment [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector declined by 0.60%, with a net outflow of 4.627 billion yuan. Out of 475 stocks in this sector, 183 stocks rose, 4 stocks hit the daily limit up, and 274 stocks fell [2] - Within the sector, 121 stocks saw net inflows, with five stocks receiving over 30 million yuan in net inflows. The top stock for net inflow was Jianfa Zhixin, with an inflow of 123 million yuan, followed by Sainuo Medical and Mindray Medical with inflows of 121 million yuan and 60.069 million yuan respectively [2] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Jianfa Zhixin: +20.00% with a turnover rate of 59.71% and a net inflow of 122.929 million yuan - Sainuo Medical: +4.74% with a turnover rate of 6.99% and a net inflow of 121.228 million yuan - Mindray Medical: +0.73% with a turnover rate of 0.41% and a net inflow of 60.069 million yuan [2] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - Shutaishen: -7.52% with a net outflow of 195.891 million yuan - Zhendai Medical: +2.51% with a net outflow of 185.422 million yuan - Yatai Pharmaceutical: -5.58% with a net outflow of 164.905 million yuan [3]